Clinical Pathology: General Principles, Hematology & Coagulation, Transfusion Medicine

• Hemophilia B is a sex-linked recessive genetic disorder leading to a deficiency in factor IX.

• Patients have a prolonged activated partial thromboplastin time, normal prothrombin time, and decreased factor IX activity.

• Hemophilia B is divided clinically into three groups: mild, greater than 5% factor IX activity; moderate, 1% to 5% factor IX activity; and severe, less than 1% factor IX activity.

• Treatment involves administration of factor IX concentrates to prevent and manage bleeding episodes.

• The factor IX dose is calculated using this formula: dose required (IU) = weight (kg) × desired factor IX increase (IU/dL) × 1 IU/kg.

• Factor IX does not remain in the intravascular space. About 50% of the administered factor IX will distribute to the extravascular space.

• Factor IX should be dosed every 24 hours due to the in vivo half-life of factor IX.



 
* = Required 
* Note Title
* Note